文献速递腹部介入US

基于多中心经动脉化疗栓塞研究数据评估超声造影无辐射治疗反应评估LI-RADS v2024

Evaluation of the Contrast-Enhanced Ultrasound Nonradiation Treatment Response Assessment LI-RADS v2024 Using Data From a Multi-Center Transarterial Chemoembolization Study.
PubMed 文献 · Acad Radiol · 2024-06-21

本研究基于既往多中心经动脉化疗栓塞队列的87例患者140个肝细胞癌病灶,回顾性评估超声造影无辐射治疗反应评估LI-RADS v2024的诊断效能。治疗后15天TR-Viable分类敏感度72.5-94.3%、特异度72.2-86.4%,30天敏感度降至65.9-84.2%、特异度升至80.0-88.0%,读者间Kappa 0.557-0.730。结论认为该标准是检测经动脉化疗栓塞后存活肿瘤的可靠工具且具有可重复性。

要点

  • 超声造影无辐射治疗反应评估LI-RADS v2024可评估经动脉化疗栓塞后病灶内及病灶周围肿瘤活性。
  • 治疗后15天TR-Viable分类敏感度72.5-94.3%、特异度72.2-86.4%。
  • 治疗后30天TR-Viable分类敏感度降至65.9-84.2%、特异度升至80.0-88.0%。

核心结论

  • 超声造影无辐射治疗反应评估LI-RADS是检测经动脉化疗栓塞后病灶存活肿瘤的可靠工具,并在不同读者间表现出可重复性。

研究设计与样本

  • 回顾性观察性研究,纳入来自既往已报道队列的87例接受经动脉化疗栓塞治疗的患者。
  • 治疗后15天和30天分别评估68个和72个肝细胞癌病灶,共分析140个肝细胞癌病灶。
  • 由三名超声造影经验不同的放射科医师独立盲法判读图像。
  • 参考标准为组织学和影像学的复合标准。

诊断标准与关键数值

  • 依据超声造影无辐射治疗反应评估LI-RADS v2024评估病灶内和病灶周围肿瘤活性,最终治疗反应评估分类为TR-Nonviable、TR-Equivocal和TR-Viable。
  • 治疗后15天TR-Viable分类的敏感度72.5-94.3%、特异度72.2-86.4%、阳性预测值86.8-91.4%、阴性预测值65.6-86.7%、准确率76.9-86.8%。
  • 治疗后30天TR-Viable分类的敏感度65.9-84.2%、阳性预测值85.7-90.6%、阴性预测值59.5-73.9%,特异度80.0-88.0%。
  • 读者间Kappa值0.557-0.730,提示中等至高度一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVE: Hepatocellular carcinoma (HCC) locoregional treatment response is commonly evaluated using the Modified Response Evaluation Criteria in Solid Tumors and the American College of Radiology (ACR) Liver Reporting and Data System (LI-RADS) Treatment Response Assessment (TRA) for MRI/CT. This study aims to evaluate the diagnostic performance of the new ACR contrast-enhanced ultrasound (CEUS) Nonradiation TRA LI-RADS v2024 in HCC treated with transarterial chemoembolization (TACE).

MATERIALS AND METHODS: This retrospective observational study included 87 patients treated with TACE from a previously reported cohort. At 15- and 30-days post-treatment, 68 and 72 HCC lesions were evaluated. Three blinded radiologists with different levels of CEUS experience interpreted the images independently. According to CEUS Nonradiation TRA LI-RADSv2024, both intralesional and perilesional tumor viability were evaluated and final TRA categories were as follows: TR-Nonviable, TR-Equivocal, and TR-Viable. The reference standard used was a composite of histology and imaging.

RESULTS: 140 HCC lesions were analyzed. At 15 days post-treatment, the sensitivity (SN), specificity (SP), positive predictive value (PPV), negative predictive value (NPV), and accuracy of TR-Viable classification ranged from 72.5-94.3%, 72.2-86.4%, 86.8-91.4%, 65.6-86.7%, 76.9-86.8%, respectively. At 30 days post-treatment, the SN, PPV, and NPV of TR-Viable classification decreased, ranging from 65.9-84.2%, 85.7-90.6%, and 59.5-73.9%, respectively, while the SP increased, ranging from 80.0-88.0%. Kappa values ranged from 0.557-0.730, indicating moderate to substantial agreement.

CONCLUSION: CEUS Nonradiation TRA LI-RADS is a reliable tool for the detection of viable tumors in lesions treated with TACE and demonstrates reproducibility across readers.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Kuon Yeng Escalante CM, Siu Xiao T, Nagaraj RU, et al. Evaluation of the Contrast-Enhanced Ultrasound Nonradiation Treatment Response Assessment LI-RADS v2024 Using Data From a Multi-Center Transarterial Chemoembolization Study. Acad Radiol. 2024. PMID: 38908918. doi:10.1016/j.acra.2024.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。